Schroders

Neurona Therapeutics is a biotechnology company developing cell-based therapies for treating neurological disorders. Founded by neuroscientists at UCSF in 2008, the company focuses on generating therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system.

Cyberhaven is a cybersecurity company that revolutionizes enterprise security by providing real-time visibility into the behavior of business-critical data. Its Data Behavior Analytics (DaBA) solution enables organizations to protect sensitive documents against cyber-attacks and insider leaks across endpoints, servers, applications, on-premise, and cloud environments. Cyberhaven simplifies security infrastructure by combining a focus on business workflows with technology that acts as an 'X-ray machine' for cyber threats.

Luminance Technologies Ltd., established in 2015 and headquartered in London, specializes in AI-driven document analysis software. It serves multinational and governmental organizations, offering a platform that accurately reviews, categorizes, and analyzes legal documents and contracts. The software identifies risk clauses, enables task allocation and progress tracking, and provides data visualization and anomaly detection. It also streamlines contract generation, negotiation, and post-execution analysis, helping businesses manage contract-related workflows efficiently.

Founded in 2016, Cera Care is Europe's largest digital-first home healthcare provider. It offers elderly care services such as dementia care, palliative care, and private nursing, delivered by over 10,000 carers daily. Leveraging AI and data analytics, Cera reduces hospitalizations by up to 70% while maintaining high-quality care.

Founded in 2016, Cera Care is Europe's largest digital-first home healthcare provider. It offers elderly care services such as dementia care, palliative care, and private nursing, delivered by over 10,000 carers daily. Leveraging AI and data analytics, Cera reduces hospitalizations by up to 70% while maintaining high-quality care.

Somagenetix is a biotechnology company specializing in gene therapy aimed at treating phagocyte-related illnesses. The firm focuses on developing innovative treatments for conditions such as immunodeficiency, neurodegeneration, and cancer with brain metastases. By utilizing genetically modified phagocytes, Somagenetix seeks to improve patient outcomes through targeted therapies. Additionally, the company is engaged in the discovery and development of stem cells derived from bone marrow and therapeutic genes from lentiviral vectors. This approach enables the correction of underlying genetic defects and the transplantation of gene-corrected cells back into patients, with the goal of curing various monogenetic diseases. Through its pioneering efforts, Somagenetix aspires to be a leader in the gene therapy sector.

Poolside is an artificial intelligence platform that offers foundation concepts and infrastructure. It aims to unlock humanity's potential by pursuing AGI for software creation, with the fundamental belief that the transitional path for humanity to AGI is by building specific capabilities instead of a general-purpose approach. It also helps users utilize the power of software creation and understand future systems.

Enfinity Global is a renewable energy company that develops, finances, constructs, operates, and owns solar and wind projects worldwide. It manages a portfolio of about 20 gigawatts of renewable energy and storage assets, including facilities already in operation and those under construction. The company pursues a net-zero carbon footprint and helps clients reduce their carbon impact while supporting a transition to a carbon-free economy. With offices in the United States, Europe, Japan, and India, Enfinity Global provides end-to-end project delivery and long-term asset ownership across global markets.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Vantage Data Centers is a global data center provider that designs, builds, and operates facilities for hyperscale, wholesale, cloud providers, and large enterprises. It offers build-to-suit data centers, powered shells, and turnkey solutions, along with move-in management, data center operations, smart hands, and facilities management services. The company emphasizes high-density, energy-efficient infrastructure and flexible environments that scale with demand, delivering reliability and sustainability. Its global footprint spans North America, Europe, the Middle East and Africa, and Asia Pacific. Headquarters are in Santa Clara, California, with an additional location in Quincy, Washington. Founded in 2010, Vantage serves clients requiring scalable, resilient data center capacity.

Firenze is a financial services company that specializes in providing investment-backed loans to a broader audience, with a focus on mass affluent clients. Its core business is operating a loan platform that offers loans to clients of wealth managers, advisers, and investment platforms. The platform extends credit based on conservative lending principles, using liquid financial assets as collateral. Firenze's mission is to democratize Lombard lending, making it more accessible to a wider range of individuals, recognizing its role in wealth creation and preservation.

Neurona Therapeutics is a biotechnology company developing cell-based therapies for treating neurological disorders. Founded by neuroscientists at UCSF in 2008, the company focuses on generating therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Prodigy Finance Limited is an online platform headquartered in London, United Kingdom, that facilitates education loans for international postgraduate and MBA students. Established in 2006, the company connects student borrowers with a community of lenders, including alumni, institutional investors, and qualified private investors. Prodigy Finance specifically targets students pursuing master's degrees across 18 countries, aiming to enhance access to higher education for those who may lack traditional financing options. In addition to its loan services, the company offers a mobile app that allows users to manage and access their loan information conveniently. Through its community funding model, Prodigy Finance addresses the financial barriers that students face, making it easier for them to pursue their academic aspirations at premium business schools.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Cohere is a platform offering developers and businesses access to advanced natural language processing (NLP) capabilities powered by cutting-edge large language models. It enables the creation of machines that understand and interpret human language safely, benefiting various industries by enhancing comprehension capabilities and facilitating more personalized user experiences.

Fastned constructs and operates fast-charging networks for electric vehicles, with a mission to accelerate sustainable mobility using renewable energy sources like solar and wind. Established in 2012, the company is headquartered in Amsterdam, Netherlands.

Casma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy. Founded in 2017, the company aims to enhance autophagy to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing significant medical challenges. Casma Therapeutics is advancing preclinical programs targeting various conditions, including muscle disorders, liver disease, inflammatory disorders, and neurodegenerative diseases. By harnessing and manipulating the autophagy system, the company seeks to arrest or reverse disease progression, ultimately enabling physicians to meet unmet medical needs and provide effective treatments for patients with serious health issues.

Fastned constructs and operates fast-charging networks for electric vehicles, with a mission to accelerate sustainable mobility using renewable energy sources like solar and wind. Established in 2012, the company is headquartered in Amsterdam, Netherlands.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Founded in 2016, Cera Care is Europe's largest digital-first home healthcare provider. It offers elderly care services such as dementia care, palliative care, and private nursing, delivered by over 10,000 carers daily. Leveraging AI and data analytics, Cera reduces hospitalizations by up to 70% while maintaining high-quality care.

Forteus is an asset management firm specializing in blockchain technology and digital assets. The company offers a variety of investment strategies that are grounded in comprehensive research, advanced technology, and rigorous risk management practices. Forteus focuses on creating tailored portfolios that include external managers, yield generation opportunities, actively managed thematic portfolios, and tokenization solutions. Through these offerings, the firm enables investors to engage with emerging trends and diversified investment strategies within the digital asset landscape.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Redcliffe Labs is a diagnostics service provider focused on identifying both communicable and non-communicable diseases through advanced radiography and pathology services. The company offers a comprehensive range of standard and specialized tests, utilizing cutting-edge laboratories and in-house technology. Redcliffe Labs aims to enhance accessibility to health tests for all individuals in India by leveraging its trusted radiology network and innovative testing methodologies. Additionally, the company specializes in reproductive health testing, cancer gene diagnosis, and screening for rare diseases, ensuring patients receive thorough support, including regular counseling and clinical data management. Through its extensive testing capabilities, Redcliffe Labs is committed to addressing various aspects of health, pregnancy, and fertility care.

Founded in 2016, Healthy Workers specializes in creating healthy work environments through data-driven solutions. The company offers products like WELLBEING-SCAN and an employer dashboard to measure and improve employee well-being. They also provide consultancy services on productivity, stress management, engagement, and workplace stressors.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.

Greencoat Capital is a London-based private equity firm, founded in 2009, that specializes in growth capital investments in lower mid-market companies and infrastructure projects within the renewable energy and resource efficiency sectors. The firm focuses on Europe, particularly Northern Europe, Ireland, and Great Britain, investing between €5 million and €30 million in companies with revenues between €10 million and €50 million. Greencoat Capital provides growth capital for various situations, including working capital funding, add-on acquisitions, and capital restructuring, typically seeking a majority or significant minority stake and board representation. It also invests in individual wind farms and co-invests with other funds. The firm's portfolio spans renewable power generation, energy efficiency, energy storage, transport, and waste to energy sectors. Greencoat Capital leverages the expertise and support of its sole investor, ESB, a leading Irish utility, to provide technical rigour and operational support to its portfolio companies.

Ambys Medicines, Inc. is a biotechnology company based in Redwood City, California, focused on discovering and developing innovative therapies for severe liver diseases. Founded in 2016, Ambys aims to transform the lives of individuals suffering from liver conditions by creating advanced gene, drug, and cell therapies. The company is dedicated to restoring liver function, halting the progression of liver disease, and addressing the serious complications associated with liver failure. Through its regenerative medical therapies, Ambys seeks to provide relief to patients with chronic liver diseases, ultimately improving their quality of life.

euNetworks is a European provider of broadband infrastructure services. It specializes in offering scalable, fiber-based products such as dark fiber, metro wavelength, Ethernet, and colocation services to clients primarily in the wholesale, content, media, mobile, and finance industries.

Belenergia is a renewable energy company that focuses on the development, construction, ownership, and operation of solar photovoltaic and wind energy assets. The company specializes in creating and managing facilities that harness renewable energy sources, including biomass, biogas, and biomethane, derived from organic waste. Belenergia is committed to enhancing local communities through its projects, ensuring the efficient operation of large-scale solar power plants and other renewable energy installations worldwide. Through its expertise in energy production, the company aims to contribute to sustainable energy solutions and promote environmental stewardship.

Cairn Real Estate is an independent investment manager based in Amsterdam. They specialize in managing various assets and investments strategically. With a focus on providing personalized and tailored solutions, Cairn Real Estate works to help clients achieve their financial objectives.

Founded in 2013, AgroStar is an Indian AgTech company dedicated to empowering farmers. It offers end-to-end solutions via its omnichannel platform, providing agronomic knowledge and data-driven insights to enhance crop yield and reduce cultivation costs. Operating in five major states, AgroStar serves millions of farmers through its Agri Advisory Center, AgroStar Agri Doctor app, and retail stores.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

RF Eclipse is a commercial mortgage originator based in Sydney, Australia, specializing in providing comprehensive mortgage services to the real estate sector. The company focuses on loan origination, loan management, and funds management, catering to various segments including commercial, retail, industrial real estate, and construction. By offering tailored financial solutions, RF Eclipse aims to support real estate investors and developers in achieving their financing needs effectively.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Graphcore is a hardware systems company that develops intelligent processing units to accelerate machine learning. It designs IPUs and offers IPU-Accelerator cards that plug into servers to accelerate training and inference, and IPU-Appliance products that deliver higher performance for inference and training workloads. Founded in 2016 and headquartered in Bristol, United Kingdom, the company maintains additional locations in Palo Alto, London, Oslo, and Beijing. Its IPU architecture enables running current machine learning models orders of magnitude faster across various servers and processors, supporting a range of AI workloads.

Sandaire is an international investment company based in London, United Kingdom, specializing in serving wealthy families, private clients, charities, and foundations. Founded in 1996, the firm operates as a multi-family office, providing expert investment counsel and long-term financial support tailored to the unique goals of its clients. Sandaire focuses on creating and maintaining sustainable wealth across generations, ensuring that the financial interests of families and organizations are managed effectively.

Integrity is a life insurance provider in Australia focused on transforming the industry by offering modern and flexible insurance products. The company aims to enhance the customer experience by creating easy-to-understand and accessible products, emphasizing transparency and simplicity. With a strong commitment to service, Integrity blends industry expertise with technology to deliver customized life insurance and wealth management solutions. The company's knowledgeable team prioritizes helping clients, particularly during challenging times, and seeks to establish a new standard of trust and reliability in the life insurance sector.

Pamfleet Group is a real estate investment firm based in Hong Kong, with additional offices in Singapore. Founded in 2000 as a management buyout of Jardine Fleming’s direct property fund management business, the firm specializes in identifying and repositioning underperforming residential and commercial properties, particularly targeting B-Grade commercial real estate with potential for redevelopment. The management team has extensive experience in the Asia-Pacific region, focusing on active value creation and innovative transaction development. Pamfleet also offers real estate asset management and investment advisory services. In July 2020, Schroders acquired a majority stake in Pamfleet, and the firm now operates under the name Schroder Pamfleet.

Founded in 2001, BlueOrchard Finance is a global impact investment manager headquartered in Switzerland. It specializes in providing innovative financing solutions to microfinance institutions worldwide, aiming to advance socially responsible financial inclusion and offer attractive investment products.

MPM+ Financial PR empowers growth through sustained exposure to enhance investor & shareholder perception and value. MPM+ makes raising capital easier, creates demand for IPOs and Placings, & positions your business leaders as the Key People of Influence in your sector.

Thirdrock Group - Wealth management business provides wealth management services.

Qwil Messenger is a communication software designed to facilitate secure and compliant B2B messaging. The platform features a single chat application that enables businesses to create a GDPR-compliant communication channel for interactions with staff, clients, and partners. It allows users to initiate virtual meetings with a single click and store files securely in one location. Qwil Messenger supports integration with 200 endpoints, enabling automation as business needs evolve. The application is designed for multiple firms and their clients, providing a branded space that is fully controlled and coordinated by each organization. Its proprietary technology allows for rapid deployment across various jurisdictions, ensuring scalability and compliance in communication.

WeInvest is a digital wealth management platform based in Singapore, established in 2013. It facilitates individual investors in discovering diverse investment opportunities, including real estate, mutual funds, and deposits. The platform offers users the ability to generate investment ideas, find suitable products, track their portfolios, and connect with brokers and advisors. Additionally, WeInvest provides services designed for banks, wealth and asset managers, and independent financial advisors, allowing them to engage clients effectively, plan and monitor investments, and analyze portfolio performance. By prioritizing accessibility and transparency, WeInvest aims to simplify the investment process for a broad audience.

Algonquin SA, founded in 1998 and based in Brussels, Belgium, specializes in the investment, ownership, operation, and franchising of hotels across Europe. The company manages a portfolio of 43 hotel assets, offering over 7,500 rooms with an estimated value of €1.8 billion. Approximately half of these hotels operate under Algonquin's own brands or well-known international franchises, while the remainder is managed through agreements with major international operators. Algonquin distinguishes itself by actively engaging in hotel operations, providing expertise in both daily management tasks and real estate matters. This dual role allows Algonquin to optimize operational efficiency and enhance the value of its properties, making it an attractive partner for institutional investors, family offices, and private equity firms seeking to collaborate in dedicated investment vehicles.

Adveq, founded in 1997, is a prominent asset manager specializing in investments in private equity and real asset funds on a global scale. The firm offers tailored investment solutions that enable clients to access specific private market segments worldwide. With a strong track record, Adveq has invested in over 400 funds, consistently delivering returns across various economic conditions. Its clientele consists primarily of institutional investors, including pension funds, insurance companies, family offices, and other financial institutions from Europe, North America, and the Asia-Pacific region. Adveq has cultivated long-lasting relationships with many of its investors, establishing itself as a trusted partner in private market investing. The company operates offices in Zurich, Frankfurt, London, New York, Beijing, Shanghai, and Hong Kong, alongside an agent relationship in Sydney.

Nutmeg is a UK-based online wealth management company offering a digital discretionary investment service for individuals. Founded in 2011 and headquartered in London, it provides a platform to build and manage diversified investment portfolios, including ISAs and pensions, with a focus on easy access to investing and transparent, cost-conscious charges. The platform enables clients to choose global portfolios and have investments managed online, aiming to simplify investing and help users meet their financial goals.

Benchmark Capital, established in 2015, specializes in offering comprehensive digital wealth management solutions aimed at enhancing the growth and success of financial advisory firms. By integrating advanced technology, investment solutions, and support services, Benchmark Capital empowers over 120 leading national and regional firms to deliver differentiated client propositions. The company focuses on unifying the fragmented financial services industry, providing its clients with the tools and insights necessary to gain a competitive edge.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Nutmeg is a UK-based online wealth management company offering a digital discretionary investment service for individuals. Founded in 2011 and headquartered in London, it provides a platform to build and manage diversified investment portfolios, including ISAs and pensions, with a focus on easy access to investing and transparent, cost-conscious charges. The platform enables clients to choose global portfolios and have investments managed online, aiming to simplify investing and help users meet their financial goals.

Cazenove Capital is a London-based wealth management firm with a long history, established in 1823. It provides personalised financial planning and investment management to private clients, family offices, trusts, companies and pension plans, focusing on preserving and growing wealth. The firm collaborates with financial advisers to deliver discretionary fund management.

STW Fixed Income Management Ltd. is an employee-owned investment manager based in Santa Barbara, California, with approximately $11 billion in assets under management. Founded in 1977, the firm specializes in managing fixed income portfolios tailored for a diverse clientele, including pensions, foundations, endowments, family wealth companies, insurance companies, and various trusts. STW focuses its investments on public fixed income markets in the United States, emphasizing investment grade fixed income value securities. The firm employs both fundamental and quantitative analysis to construct its portfolios, with a particular interest in technology sectors such as technical infrastructure and software development. As a subsidiary of Schroder U.S. Holdings, Inc., STW Fixed Income Management is committed to delivering personalized investment strategies to its clients.

GeoSentric is a company based in Salo, Finland, and Amsterdam, The Netherlands, specializing in mobile digital lifestyle applications and geo-mobility social networking. Its flagship product, GyPSii, serves as a leading platform that connects people, places, and communities across various networks and devices. Utilizing patented technologies, GeoSentric facilitates the transfer and publishing of location-based information between mobile devices, enhancing user connectivity and engagement. The company operates in North America, Europe, and the Asia Pacific region, reflecting its global reach and commitment to innovation in the digital lifestyle and location services market.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

GeoSentric is a company based in Salo, Finland, and Amsterdam, The Netherlands, specializing in mobile digital lifestyle applications and geo-mobility social networking. Its flagship product, GyPSii, serves as a leading platform that connects people, places, and communities across various networks and devices. Utilizing patented technologies, GeoSentric facilitates the transfer and publishing of location-based information between mobile devices, enhancing user connectivity and engagement. The company operates in North America, Europe, and the Asia Pacific region, reflecting its global reach and commitment to innovation in the digital lifestyle and location services market.

Orthomimetics was founded in 2005 as a spin-out from the University of Cambridge and the Massachusetts Institute of Technology (MIT). Its products are based on a leading collagen biomaterials platform for the production of scaffolds for cartilage, meniscus, ligament and tendon repair. Orthomimetics’ flagship product, Chondromimetic™, is an off-the-shelf, resorbable implant for the minimally invasive repair of small osteochondral (cartilage and underlying bone) defects. The product has received European market approval (CE-Mark approval) and is close to entering the European market. Small osteochondral defects represent an important medical need that is currently not covered by TiGenix’ products. Chondromimetic™ forms an excellent fit with TiGenix’ lead product, ChondroCelect®, since both products target the same customer base in complementary indications.

Newfinance Capital is a London-based funds of hedge funds manager.

Square Enix is a Japanese video game publisher and entertainment company formed in 2003 through the merger of Square and Enix. It develops, publishes, and distributes interactive entertainment content worldwide, including franchises such as Final Fantasy, Dragon Quest, Kingdom Hearts, and Nier, and operates publishing, merchandise, and amusement businesses. The company maintains a global network of development studios across North America, Europe, and Japan and licenses its intellectual property for games, media, and related products. Square Enix supports online and cross-platform gaming and has established international brands including SQUARE ENIX and TAITO, with a presence that spans major markets through studios, offices, and partnerships. It focuses on creating and commercializing entertainment experiences across consoles, PCs, and mobile platforms, as well as media related to its game properties.

CellZome is a pharmaceutical company based in Heidelberg, Baden-Württemberg, founded in 2000. The company specializes in the discovery, development, and commercialization of kinase-targeted drugs aimed at treating inflammatory diseases. CellZome focuses on creating a pipeline of kinase inhibitors that target inflammatory mediators, developing oral therapeutics for conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma.

Founded in 1997, iCollector is a pioneering online platform connecting auction houses with buyers worldwide. With over 1000 clients, they specialize in coin auctions, vintage collectibles, and other unique items. Their main service offers pay-per-use access to their platform for listing items, facilitating real-time bidding, and providing comprehensive support before, during, and after each auction.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Azafaros develops therapeutic agents for treating rare metabolic disorders, specifically lysosomal storage disorders (LSDs), via oral administration of azasugar compounds. These innovative agents were discovered by Professor Hans Aerts and are licensed exclusively to Azafaros.